SUWON, South Korea--(BUSINESS WIRE)--OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, today announced that the Company identified effective inhibition of target ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback